Print

Opexa Therapeutics (OPXA) Announces Pricing of Public Offering of Common Stock  
8/8/2013 9:52:29 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing Tcelna®, a patient-specific T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the pricing of an underwritten public offering of 12 million shares of its common stock at a price to the public of $1.50 per share. The gross proceeds to Opexa from this offering are expected to be approximately $18 million, before deducting underwriting discounts and commissions and other estimated offering expenses. All of the shares in the offering are to be sold by Opexa. Opexa has also granted the underwriters a 30-day option to purchase up to an additional 1.8 million shares of common stock to cover over-allotments, if any. The offering is expected to close on or about August 13, 2013, subject to customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.

//-->